Risk-Benefit Analysis is the process of weighing a medical device’s expected clinical benefits against its residual risks to determine whether the device remains acceptable for its intended use.
Required under ISO 14971, the analysis becomes necessary when a residual risk cannot be judged acceptable through risk-control measures alone. The manufacturer must provide objective evidence and documented reasoning showing that the anticipated medical benefits outweigh the remaining risk.
What is Risk-Benefit Analysis?
Risk-Benefit Analysis, also called benefit-risk analysis, is an important decision point within the medical-device risk-management process. After identifying hazards, estimating risks and applying appropriate risk controls, some residual risk will usually remain.
ISO 14971:2019 requires manufacturers to evaluate whether each residual risk and the device’s overall residual risk meet the acceptability criteria defined in the risk-management plan. When a residual risk is not acceptable and further risk reduction is not practicable, the manufacturer must determine whether the expected benefits of the device outweigh that risk.
A formal Benefit-Risk Determination combines engineering risk information with clinical and regulatory evidence. Engineering teams supply data concerning hazards, probability of harm, severity and the effectiveness of implemented controls. Clinical and regulatory teams provide evidence demonstrating the nature, probability, magnitude and duration of the expected patient benefits.
The resulting analysis should explain:
- Which residual risks remain
- Why further risk reduction is not reasonably practicable
- What medical benefits the device provides
- Which patients are expected to benefit
- The quality and relevance of the supporting evidence
- Why the benefits outweigh the remaining risks
- Which post-market information will be monitored
The conclusion and its supporting evidence are documented in the risk-management file for review by quality teams, regulators and auditors.
Why Risk-Benefit Analysis matters in medical-device development
An incomplete or poorly supported benefit-risk determination can lead to regulatory questions, additional evidence requests or delayed market authorization.
Under EU MDR 2017/745 Annex I, manufacturers must reduce risks as far as possible without adversely affecting the benefit-risk ratio and demonstrate that residual risks are acceptable when weighed against the device’s benefits. The conclusion must remain consistent with the clinical evaluation, risk-management file, labeling and post-market plans.
FDA reviewers apply comparable benefit-risk reasoning during 510(k), De Novo and PMA reviews. Known device risks do not automatically prevent market authorization, but the manufacturer must demonstrate that the probable benefits justify those risks for the proposed patient population and conditions of use.
Poor risk-benefit work can result in:
- Delayed regulatory submissions
- Additional Information requests
- Notified-body findings
- Unsupported clinical claims
- Inadequate warnings or contraindications
- Late design changes
- Expanded clinical-evidence requirements
- Recalls or field actions when new safety signals emerge
There is also a development-cost consequence. Reconstructing a risk-management file after design freeze is slow and expensive. Teams that treat benefit-risk analysis as a late compliance exercise may discover that they lack the necessary clinical evidence or that unresolved risks require a substantial redesign.
Effective teams establish the benefit and risk strategy while requirements, clinical claims and risk controls can still influence the design.
How Risk-Benefit Analysis works
The process follows a defined sequence under ISO 14971. Its depth should be proportionate to the device’s classification, novelty, intended use and risk profile.
1. Establish risk-acceptability criteria
The manufacturer defines the criteria used to evaluate individual and overall residual risks in the risk-management plan.
These criteria should be established before risk analysis begins. Writing or changing them after reviewing the results can make the eventual conclusions appear arbitrary or outcome-driven.
Risk-acceptability criteria may consider:
- Applicable regulations and standards
- Generally acknowledged state of the art
- Comparable devices
- Severity and probability of harm
- Intended patient population
- Clinical context
- Available alternative treatments
- Stakeholder expectations
- The manufacturer’s risk-management policy
2. Identify hazards and estimate risks
The team identifies reasonably foreseeable hazards, hazardous situations and potential harms associated with the device.
Risk analysis considers factors such as:
- Severity of potential harm
- Probability of the hazardous situation
- Probability that the situation results in harm
- Normal use
- Reasonably foreseeable misuse
- Use errors
- Software failures
- Component and subsystem failures
- Manufacturing defects
- Environmental conditions
- Cybersecurity events where relevant
The analysis should be updated throughout development as the design, intended use and available evidence evolve.
3. Implement risk controls
ISO 14971 establishes a priority order for risk-control measures:
- Inherent safety through design
- Protective measures in the device or manufacturing process
- Information for safety, including warnings, precautions and training
Information for safety should not replace a feasible design control. The manufacturer must evaluate each control’s implementation and effectiveness and determine whether it creates any new risks.
Appropriate verification and validation evidence should demonstrate that risk controls have been correctly implemented and effectively reduce risk as intended.
4. Evaluate residual risk
After applying risk controls, the team estimates the risk that remains and compares it with the predefined acceptability criteria.
A residual risk may be:
- Acceptable without further action
- Unacceptable and requiring additional risk reduction
- Unacceptable through risk criteria alone but potentially justifiable through benefit-risk analysis
The team should not move directly to benefit-risk justification if another practicable design or protective measure could reduce the risk further.
5. Define the expected medical benefits
Benefits should be stated in measurable, patient-relevant terms rather than broad assertions such as “improves care.”
Relevant benefit characteristics include:
- Type of clinical benefit
- Magnitude of improvement
- Probability that patients will experience the benefit
- Duration of the benefit
- Time until the benefit occurs
- Importance of the treated condition
- Availability and performance of alternative treatments
- Value to the intended patient population
- Benefits to clinicians or caregivers where they affect patient outcomes
Economic or commercial advantages do not justify exposing patients to medical risk.
6. Assemble supporting clinical evidence
Benefit claims require credible evidence. Relevant sources may include:
- Published scientific literature
- Clinical evaluation data
- Performance studies
- Usability studies
- Real-world evidence
- Comparable or equivalent devices
- Post-market information
- Device-specific clinical data
- Results from a clinical investigation
The evidence should match the device’s intended purpose, patient population, indications, operating principle and clinical claims. Evidence from a substantially different device or population may not provide adequate support.
For EU MDR devices, this work should remain consistent with the Clinical Evaluation Report. For IVDs, the corresponding performance-evaluation evidence must support the claimed clinical benefit and intended purpose.
7. Compare benefits with residual risks
The manufacturer evaluates the identified benefits against the nature and magnitude of the remaining risks.
This is not necessarily a simple numerical calculation. Benefits and risks may use different measures, and some harms may be severe but rare. The analysis should therefore provide a transparent, evidence-based rationale addressing:
- The severity and probability of residual harms
- The magnitude and probability of clinical benefit
- Uncertainty in the available evidence
- The affected patient population
- Available therapeutic or diagnostic alternatives
- The consequences of not using the device
- Whether warnings or training can further support safe use
- Whether additional evidence or monitoring is necessary
The reasoning should be clear enough for an independent reviewer to follow from the evidence to the conclusion.
8. Document and approve the conclusion
The analysis and supporting rationale should be recorded in the risk-management file. Relevant information may also appear in:
- Risk-management report
- Clinical Evaluation Report
- Technical documentation
- Design History File
- Instructions for Use
- Product labeling
- Post-market surveillance plan
- Periodic Safety Update Report
The decision should receive appropriate cross-functional review and approval from engineering, quality, clinical and regulatory representatives.
9. Reassess the balance after launch
Risk-Benefit Analysis is not a one-time premarket activity. New information can change the estimated probability or severity of harm, reveal previously unknown hazards or provide better evidence of clinical benefit.
Relevant post-market inputs include:
- Complaints
- Adverse events
- Vigilance reports
- CAPA investigations
- Field safety corrective actions
- Published literature
- Trend reports
- Service and repair information
- New clinical evidence
- Changes in the state of the art
- Post-market studies
For applicable devices, Post-Market Clinical Follow-Up (PMCF) helps confirm ongoing safety and performance, address unanswered clinical questions and determine whether the original benefit-risk conclusion remains valid.
Risk-Benefit Analysis for software-driven devices
Software introduces additional considerations because faults may affect multiple device functions simultaneously and software failures are often systematic rather than random.
IEC 62304 lifecycle records can provide evidence concerning:
- Software safety classification
- Software requirements
- Architectural risk controls
- Anomaly management
- Verification coverage
- Change control
- Maintenance and problem resolution
Usability engineering under IEC 62366-1 also contributes to the analysis because use error can be a major source of residual risk. The team should consider whether the interface, labeling, alarms or workflow could cause users to misunderstand information or perform an unsafe action.
Cybersecurity risks may also influence the benefit-risk conclusion for connected devices. Vulnerabilities affecting availability, integrity or confidentiality may create patient-safety consequences requiring risk controls and post-market monitoring.
Common challenges and best practices
Defining acceptability criteria after the analysis
If risk-acceptability criteria are written after the team knows the results, the criteria may appear designed to justify an existing product rather than guide objective decisions.
Define and approve the criteria during risk-management planning.
Using vague benefit statements
Statements such as “the device improves outcomes” do not provide enough information for a defensible comparison. Benefits should identify the affected population, clinical outcome, magnitude, probability and duration.
Relying on weak or irrelevant clinical evidence
Detailed engineering risk information cannot compensate for an unsupported benefit claim. The evidence must be relevant to the actual device, intended use, population and clinical claims.
Using benefit-risk analysis instead of reducing risk
Benefit-risk reasoning should not be used to avoid a feasible design improvement. Risk controls must be applied in the required priority order before the manufacturer relies on benefits to justify the remaining risk.
Ignoring uncertainty
Available data may contain uncertainty concerning event rates, long-term performance or rare harms. The analysis should acknowledge these limitations and explain how labeling, monitoring or additional studies will manage them.
Failing to update the conclusion
A risk-management file that is not updated after launch cannot reflect actual field performance. Post-market information should feed back into the risk evaluation and benefit-risk determination.
Inconsistency between controlled documents
The intended use, clinical claims, risks and benefits should remain consistent across the risk-management file, Clinical Evaluation Report, technical documentation, IFU and promotional materials.
Risk-Benefit Analysis best practices
Strong programs generally:
- Establish risk-acceptability criteria before risk analysis.
- Connect each identified risk with its controls and verification evidence.
- Define benefits in measurable, clinically meaningful terms.
- Involve clinical and regulatory specialists early.
- Use evidence relevant to the intended population and purpose.
- Document uncertainties and evidence limitations.
- Explain why further risk reduction is not practicable.
- Maintain consistency between risk, clinical and labeling documents.
- Assign clear cross-functional approval responsibility.
- Define post-market indicators that could trigger reassessment.
- Revisit the conclusion following significant design or intended-use changes.
How SJML helps with Risk-Benefit Analysis
SJML supports Risk-Benefit Analysis through its medical device compliance services, integrating engineering risk information with clinical and regulatory evidence.
SJML’s engineering teams apply ISO 14971 risk analysis and risk controls alongside design, verification and design-transfer activities. This ensures that residual-risk information and verification evidence are generated during development instead of being reconstructed shortly before submission.
QARA specialists support clinical evaluation, technical documentation, regulatory strategy and the evidence base required for a defensible benefit-risk conclusion. Post-market and regulatory-sustenance support helps manufacturers maintain risk files and reassess conclusions as complaints, clinical information and safety signals emerge.
This support spans development from early concept through market release and post-market surveillance for startups and established medical-device OEMs.
Frequently asked questions
Risk assessment identifies hazards and estimates the probability and severity of harm. Risk-benefit analysis is a later step, used only when residual risk from that assessment fails to meet acceptability criteria on its own. It weighs the remaining risk against clinical benefit to decide whether the device is still acceptable to release.
It’s required whenever residual risk, for an individual hazard or the device overall, isn’t judged acceptable through standard risk control alone. ISO 14971 makes this mandatory at that point, and EU MDR Annex I requires the same benefit-risk weighing as part of general safety and performance requirements.
ISO 14971:2019 is the primary standard, defining how manufacturers estimate residual risk and weigh it against benefit. EU MDR 2017/745 Annex I and FDA guidance on benefit-risk factors both reference the same underlying logic for regulatory submissions.
The device cannot be released as designed. The manufacturer must reduce risk further through design changes or added protective measures, gather stronger clinical evidence, or, in some cases, narrow the intended use until the balance becomes acceptable.
It’s a cross-functional judgment, not one function’s call. Engineering supplies risk data, clinical and regulatory affairs supply benefit evidence, and quality and regulatory leadership typically review and sign off before it enters the risk management file.